Catalent to Open Second Clinical Supply Facility in ChinaCatalent Pharma Solutions plans to invest $2.5 million in a new, second clinical supply facility in Shanghai, China, due to open in early 2019. When completed, the 30,000-square-feet facility is expected to employ 100 people and double Catalent’s total clinical storage capacity in China.

Continuous bioprocessing involves integration of what are typically batch-based, separate manufacturing steps into a connected process, enabling continuous flow from the addition of raw materials through product harvest, purification and testing, according to information from MilliporeSigma.

Samsung BioLogics transferred 9,226,068 shares of Samsung Bioepis to Biogen on November 7th, 2018, and Biogen paid Samsung BioLogics about KRW 759.5 billion ($674 million), including the amount and interest of the acquired shares.

Samsung BioLogics and Biogen agreed on the call option that Biogen could purchase up to 50% -1 stake in Samsung Bioepis at the time of signing shareholders’ agreement for the establishment of the joint venture, Samsung Bioepis, in December 2011. Biogen exercised the call option in June 2018.

Metrics Contract Services Expands Granulation Capabilities Metrics Contract Services, the contract pharmaceutical development and manufacturing division of Mayne Pharma, has announced the successful qualification of two commercial bottling lines for serialization at its new $80-million oral solid-dose commercial manufacturing site in Greenville, North Carolina.

As part of the Greenville site expansion, packaging capacity has more than doubled. One bottling line is dedicated for clinical packaging, and two commercial bottling lines have been qualified for serialization. The investment in the lines for serialization were made to comply with the new requirements associated with the US Drug Supply Chain Security Act, which are subject to enforcement starting November 2018, according to the company.

PMI Biopharma Solutions Names CEOPMI BioPharma Solutions, a new contract development and manufacturing organization (CDMO) formed in January of 2018, appointed David Sunseri, PhD, as Chief Executive Officer, effective August 2018. The company announced the appointment earlier this month (November 2018). He previously served as Senior Vice President, Pharmaceutical Development and Chief Business Development Officer at PMI BioPharma Solutions.

Prior to PMI Bio, Dr. Sunseri spent almost four years at Berg, LLC, a Framingham, Massachusetts-based clinical-stage biopharmaceutical company, in positions of increasing responsibility leading all aspects of chemistry, manufacturing and control (CMC) during this time. Most recently, he was the Vice President, Product Development responsible for clinical trial manufacturing, engineering operations, supply chain, and formulations. He spent approximately 10 years with Schering-Plough and Merck & Co. in small molecule inhalation and parenteral development and commercial manufacturing of inhalation and medical device products.

Science Exchange Partners with Corning Science Exchange, a Palo Alto, California-headquartered enterprise platform for outsourced research and development services, has partnered with Corning Life Sciences, to offer online access to Corning’s ADME (absorption, distribution, metabolism, and excretion)/Tox services to scientists.